Restorative treatments for osteoarthritis

There’s no cure for osteoarthritis. Current treatment for this debilitating joint disease involves managing symptoms and replacing joints.

Professor Francesco Dell’Accio and his team have invented three novel and potentially groundbreaking experimental treatments to eliminate pain and reverse the structural changes caused by osteoarthritis.

ROR2: Novel target for the promotion of healthy cartilage in osteoarthritis

This unique therapy targets ROR2, a non-redundant marker expressed minimally in adult tissues. It’s success hinges on a unique approach, leveraging a novel cell-surface receptor that is specifically upregulated in cartilage due to local inflammation and mechanical stress, while maintaining minimal expression in physiological conditions. In doing so, this therapy will both prevent further cartilage degradation and introduce cartilage formation.

Agrin for the treatment of osteoarthritis

Agrin supports cartilage repair by modulating various molecular mechanisms, including Wnt signalling. Queen Mary researchers have identified modified, soluble polypeptides derived from human agrin or its variants and shown that they can promote chondrocyte differentiation and chondrogenesis.

The small, soluble polypeptides overcome potential rejection issues, induce the recruitment of mesenchymal stem cells for cartilage repair, and support the formation of stable cartilage without bone transformation, making it a promising therapeutic approach.

A molecule to promote cartilage regeneration and treat osteoarthritis

Protein Z is an engineered secreted protein ligand of CXCR1 and CXCR2 receptors developed by Queen Mary researchers. When repeatedly injected into joints, it protects against cartilage degeneration and eliminates pain in osteoarthritis models.

Since Protein Z is a modified protein that naturally occurs in the body, there is less risk of rejection. Furthermore, unlike other proteins that can induce cartilage formation, Protein Z supports the creation of stable cartilage without the risk of transforming into bone, making it a promising candidate for osteoarthritis treatment. Its mechanisms of action have been thoroughly characterised, enhancing its potential in clinical applications.

Early tests show promising results, so we’re looking for a commercial partner to help us develop these groundbreaking treatments.